Peking University Third Hospital Drug Clinical Trial Institution Participates in 2025 DIA Global Annual Meeting

Author: Me Xueting

https://www.puh3.net.cn/info/1971/153291.htm

        From May 22 to 25, 2025, the 2025 DIA Global Annual Meeting and Exhibition, hosted by the Drug Information Association (DIA), was held in Shanghai. Peking University Third Hospital was invited to participate and set up a booth. Li Haiyan, Director of the Drug Clinical Trial Institution, delivered an academic report titled "From the Perspective of Medical Institutions and Investigators: The Implementation and Realization of E6(R3) Concepts," and participated in a roundtable discussion. Wang Fangfang, Chief Physician of the Phase I Clinical Research Ward, and Zhao Lin, Attending Physician, respectively delivered academic reports titled "Case Sharing of Phase I Clinical Trials in siRNA Cardiovascular Drug Development" and "Controlling Risk at the Source—Key Safety Strategies in Phase I Clinical Trial Protocol Design." During the conference, Director Li Haiyan led her team to receive leaders from relevant competent authorities, as well as colleagues from industry, academia, and the pharmaceutical sector, at the exhibition booth. 

Peking University Third Hospital Experts Deliver Reports

Peking University Third Hospital Drug Clinical Trial Institution Team Participates in Exhibition and Introduces Relevant Information